Naoki Furuya

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi et al. · JAMA Oncology · 2021 · 178 citations · Full text

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

Satoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu et al. · Journal of Thoracic Oncology · 2020 · 96 citations · Full text

Translational Medicine, Antibiotics, Pretreated Nsclc +5

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy

Yuka Ito, Takashi Tsuda, Hiroko Minatogawa et al. · Journal of Clinical Oncology · 2018 · 68 citations

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Hiroki Izumi, Shingo Matsumoto, Jie Liu et al. · Nature · 2021 · 68 citations · Full text

Oncogenic Agent, Medicine, Non‐small‐cell Lung Cancer +10